Acid Stable Protease

Pathways Recommended:	Metabolic Enzyme/Protease

By Targets:	HCV Protease (1) HIV Protease (3) Virus Protease (3) Amyloid-β (1) Apoptosis (1) Bacterial (2) Biochemical Assay Reagents (2) COX (1) Dengue Virus (1) Endogenous Metabolite (1) Fluorescent Dye (1) HIV (1) NO Synthase (2) PROTACs (1) Reactive Oxygen Species (ROS) (1) SARS-CoV (6) Sirtuin (1)
By Research Areas:	Infection (14) Inflammation/Immunology (1) Neurological Disease (1)

Targets Recommended: Virus Protease HCV Protease HIV Protease Protease Activated Receptor (PAR) ClpP TMPRSS6 Calpain Serpin Enteropeptidase Ser/Thr Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-110210

BODIPY-FL NHS ester BODIPY FL,SE	Fluorescent Dye	Others
BODIPY FL NHS ester (BODIPY FL, SE) is a cell membranes-penatrable amine-reactive fluorescent probe. The maximum excitation/emission wavelength of the BODIPY-FL NHS ester are 502/511 nm, respectively. BODIPY-FL NHS ester has high stability and is insensitive to the polarity, pH and type of solvent, and can maintain stable fluorescence properties under different environmental conditions. BODIPY-FL NHS ester can be used for the synthesis of protease substrates, live cell imaging, protein labeling and immunoassay .

HY-Y0308H

Sodium phosphate dibasic, for molecular biology Disodium hydrogen phosphate, for molecular biology	Biochemical Assay Reagents	Others
Sodium phosphate dibasic (Disodium hydrogen phosphate), for molecular biology, is a type of phosphate salt that can be used in molecular biology research to prepare stable buffers free of RNase/DNase/protease .

HY-E70331

Acid Stable Protease	Endogenous Metabolite	Others
Acid Stable Protease is a biocatalyst and a key enzyme in new biocatalyst technology. Enzyme engineering focuses on enhancing enzyme reaction kinetics, substrate selectivity, and activity under harsh conditions such as low or high pH. By introducing stimulus responsiveness to these enzyme modifications, dynamic control of activity is also possible .

HY-169847

ZK-806450	SARS-CoV Dengue Virus	Infection
ZK-806450 is a compound with antiviral activity. ZK-806450 has a high binding potential to the allosteric binding site of the SARS-CoV-2 3CL protease. ZK-806450 can also specifically and stably bind to the GAG site of the dengue virus envelope protein .

HY-P10383

SPSB2-iNOS inhibitory cyclic peptide-1	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

HY-W013964

4-Iodobenzylamine (4-Iodophenyl)methanamine	Biochemical Assay Reagents	Others
4-Iodobenzylamine ((4-Iodophenyl)methanamine) is a probe that can detect the binding patterns of serine proteases that are like trypsin, as well as urokinase-type plasminogen activator (uPA). 4-Iodobenzylamine is stable in aqueous solution .

HY-162525

GS-9770	HIV Protease	Infection
GS-9770 is an orally active inhibitor for HIV protease with K_i of 0.16 nM. GS-9770 exhibits antiviral activity aginst HIV-1 strains and HIV-2 strains with EC₅₀ of 1.9-26 nM, and 26 nM. GS-9770 is metabolic stable in human liver microsomes. GS-9770 exhibits good pharmacokinetic characters in Sprague Dawley rats .

HY-N8693

Withanoside IV	COX Amyloid-β Sirtuin Reactive Oxygen Species (ROS) Apoptosis SARS-CoV	Infection Neurological Disease
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .

HY-P5924A

D-K6L9	Bacterial	Infection
D-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. D-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance .

HY-P5924

L-K6L9	Bacterial	Infection
L-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. L-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance .

HY-P10383A

SPSB2-iNOS inhibitory cyclic peptide-1 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-1(HY-P10383). SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

HY-183661

SCHEMBL12616233	SARS-CoV	Infection
SCHEMBL12616233 is a SARS-CoV-2 main protease (M_Pro) inhibitor. SCHEMBL12616233 binds to the active cavity of SARS-CoV-2 M_Pro and forms a stable complex. SCHEMBL12616233 can be used for the research of covid-19 .

HY-180567

PAC-Phe-Val	HIV Protease	Infection Inflammation/Immunology
PAC-Phe-Val is a potent HIV-1 protease inhibitor with an IC₅₀ value of 33.10 nM. PAC-Phe-Val forms stable and strong interactions with critical active site residues, contributing to its high inhibitory potency. PAC-Phe-Val can be used for HIV/AIDS research .

HY-167293

Deldeprevir ACH-2684; Neceprevir	HCV Protease	Infection
Deldeprevir (ACH-2684) is a HCV NS3 protease inhibitor. Deldeprevir has potent antiviral activities against different genotypes and against known resistant variants (such as R155, Al56 and D168) by the formation a highly stable complex with NS3 prolease. Deldeprevir can be used for Hepatitis C virus infection research .

HY-181888

GRL-142	HIV HIV Protease	Infection
GRL-142 is a potent HIV-1 protease inhibitor capable of crossing the blood-brain barrier. GRL-142 exhibits extremely high inhibitory activity against both wild-type and multidrug-resistant strains (IC₅₀=0.0094 nM). GRL-142 acts synergistically with the P2/P2' segments via a unique scaffold binding mechanism, utilizes fluorine-mediated stable interactions to maintain its bioactive conformation, adapts to p51 HIV-1 protease mutants, and maintains the flap-closed state by directly acting on the flap tip residues. GRL-142 disrupts the flap-water hydrogen bond network of wild-type protease, thereby effectively blocking viral replication. GRL-142 can be used to study HIV-1 infection and the associated neurocognitive disorder (HAND) .

HY-127083

Artecanin	SARS-CoV Virus Protease	Infection
Artecanin is a *SARS-CoV-2 main protease* (M ^pro) inhibitor with predicted high gastrointestinal absorption and oral bioavailability, and no predicted hepatotoxicity, carcinogenicity, mutagenicity or cytotoxicity. Artecanin interacts with His41 and Cys145, the key amino acid residues in the active site of M ^pro*, blocks the cleavage and maturation of viral precursor proteins, and forms a stable* complex with M ^pro. Artecanin blocks the invasion of SARS-CoV-2. Artecanin is applicable to the research of COVID-19 .

HY-181193

PROTAC SARS-CoV-2 Mpro degrader-7	PROTACs SARS-CoV Virus Protease	Infection
PROTAC SARS-CoV-2 Mpro degrader-7 is a *SARS-CoV-2 main protease* (Mpro) PROTAC degrader with a DC₅₀** of 0.985 μM. PROTAC SARS-CoV-2 Mpro degrader-7 promotes K48-linked polyubiquitination of SARS-CoV-2 Mpro, leading to proteasome-dependent degradation via the ubiquitin-proteasome system.PROTAC SARS-CoV-2 Mpro degrader-7 forms a ternary complex with SARS-CoV-2 Mpro and CRBN E3 ubiquitin ligase to enable viral protease ubiquitination.PROTAC SARS-CoV-2 Mpro degrader-7 exhibits a high selectivity index, and induces dose-dependent degradation of SARS-CoV-2 Mpro in stable cells expressing the viral protease.PROTAC SARS-CoV-2 Mpro degrader-7 can be used for the research of COVID-19 .

HY-181263

Jun13698	SARS-CoV Virus Protease	Infection
Jun13698 is a SARS-CoV-2 main protease (M ^pro) inhibitor with K_i values of 65.6 nM, 510.0 nM, and 117.5 nM against the wild-type, E166V, and E166A mutants, respectively. Jun13698 forms stable complexes with wild-type and mutant M ^pro to mediate enzyme inhibition. Jun13698 exhibits antiviral activity against SARS-CoV-2 variants carrying the E166V/A mutation. Jun13698 is applicable to COVID-19-related research .

Cat. No.	Product Name

HY-LD004

DEL Covalent Library	14 million compounds
DEL technology enables the simultaneous screening of millions or billions of compounds in a single tube by covalently linking each small molecule with a unique DNA sequence. Traditional DEL screening primarily focuses on identifying non-covalent binding molecules, where interactions with the target are reversible. In contrast, DNA‑encoded covalent library is an ultra‑high‑throughput screening library developed on the basis of conventional DNA‑encoded library technology. It incorporates controllable electrophilic covalent warheads capable of forming irreversible covalent bonds with amino acid residues at the active sites of target proteins, including Cys, Lys, Ser, Tyr, and others. This covalent binding enhances binding affinity, prolongs residence time at the target site, and has the potential to overcome challenges associated with traditional non-covalent inhibitors, such as drug resistance or off-target effects. Each compound in the library contains both a binding domain and an electrophilic warhead. It first recognizes and binds to the target through non covalent interactions, and then forms a stable covalent bond with key amino acid residues to achieve irreversible inhibition. This library is specifically designed for the discovery of potent, long lasting, and highly selective covalent inhibitors, particularly for undruggable targets such as kinases, GPCRs, proteases, and mutant oncoproteins. Each molecule is uniquely labeled with a DNA barcode for molecular identification and sequencing decoding. This library is an advanced and highly diverse collection, consists of 35 independent sub-libraries with a total scaleof 14 million compounds, It incorporates over 14 experimentally validated covalent warheads capable of targeting cysteine, lysine, arginine, aspartic acid and glutamic acid. This library is constructed with diverse drug like core scaffolds and integrated controllable covalent warheads, it features structural diversity, reaction spec

DEL Covalent Library

14 million compounds

DEL technology enables the simultaneous screening of millions or billions of compounds in a single tube by covalently linking each small molecule with a unique DNA sequence. Traditional DEL screening primarily focuses on identifying non-covalent binding molecules, where interactions with the target are reversible. In contrast, DNA‑encoded covalent library is an ultra‑high‑throughput screening library developed on the basis of conventional DNA‑encoded library technology. It incorporates controllable electrophilic covalent warheads capable of forming irreversible covalent bonds with amino acid residues at the active sites of target proteins, including Cys, Lys, Ser, Tyr, and others. This covalent binding enhances binding affinity, prolongs residence time at the target site, and has the potential to overcome challenges associated with traditional non-covalent inhibitors, such as drug resistance or off-target effects.

Each compound in the library contains both a binding domain and an electrophilic warhead. It first recognizes and binds to the target through non covalent interactions, and then forms a stable covalent bond with key amino acid residues to achieve irreversible inhibition. This library is specifically designed for the discovery of potent, long lasting, and highly selective covalent inhibitors, particularly for undruggable targets such as kinases, GPCRs, proteases, and mutant oncoproteins. Each molecule is uniquely labeled with a DNA barcode for molecular identification and sequencing decoding.

This library is an advanced and highly diverse collection, consists of 35 independent sub-libraries with a total scaleof 14 million compounds, It incorporates over 14 experimentally validated covalent warheads capable of targeting cysteine, lysine, arginine, aspartic acid and glutamic acid. This library is constructed with diverse drug like core scaffolds and integrated controllable covalent warheads, it features structural diversity, reaction spec

Cat. No.	Product Name	Type

HY-110210

BODIPY-FL NHS ester BODIPY FL,SE	Fluorescent Dyes
BODIPY FL NHS ester (BODIPY FL, SE) is a cell membranes-penatrable amine-reactive fluorescent probe. The maximum excitation/emission wavelength of the BODIPY-FL NHS ester are 502/511 nm, respectively. BODIPY-FL NHS ester has high stability and is insensitive to the polarity, pH and type of solvent, and can maintain stable fluorescence properties under different environmental conditions. BODIPY-FL NHS ester can be used for the synthesis of protease substrates, live cell imaging, protein labeling and immunoassay .

BODIPY-FL NHS ester

BODIPY FL,SE

Fluorescent Dyes

BODIPY FL NHS ester (BODIPY FL, SE) is a cell membranes-penatrable amine-reactive fluorescent probe. The maximum excitation/emission wavelength of the BODIPY-FL NHS ester are 502/511 nm, respectively. BODIPY-FL NHS ester has high stability and is insensitive to the polarity, pH and type of solvent, and can maintain stable fluorescence properties under different environmental conditions. BODIPY-FL NHS ester can be used for the synthesis of protease substrates, live cell imaging, protein labeling and immunoassay .

Cat. No.	Product Name	Type

HY-Y0308H

Sodium phosphate dibasic, for molecular biology Disodium hydrogen phosphate, for molecular biology	Biochemical Assay Reagents
Sodium phosphate dibasic (Disodium hydrogen phosphate), for molecular biology, is a type of phosphate salt that can be used in molecular biology research to prepare stable buffers free of RNase/DNase/protease .

Cat. No.	Product Name	Target	Research Area

HY-P10383

SPSB2-iNOS inhibitory cyclic peptide-1	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

HY-P5924A

D-K6L9	Bacterial	Infection
D-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. D-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance .

HY-P5924

L-K6L9	Bacterial	Infection
L-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. L-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance .

HY-P10383A

SPSB2-iNOS inhibitory cyclic peptide-1 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-1(HY-P10383). SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8693

Withanoside IV	Structural Classification Withania somnifera Solanaceae Plants Steroids Source Classification	COX Amyloid-β Sirtuin Reactive Oxygen Species (ROS) Apoptosis SARS-CoV
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .

HY-127083

Artecanin	Structural Classification Natural Products Laurus nobilis L. Plants Lauraceae Source Classification	SARS-CoV Virus Protease
Artecanin is a *SARS-CoV-2 main protease* (M ^pro) inhibitor with predicted high gastrointestinal absorption and oral bioavailability, and no predicted hepatotoxicity, carcinogenicity, mutagenicity or cytotoxicity. Artecanin interacts with His41 and Cys145, the key amino acid residues in the active site of M ^pro*, blocks the cleavage and maturation of viral precursor proteins, and forms a stable* complex with M ^pro. Artecanin blocks the invasion of SARS-CoV-2. Artecanin is applicable to the research of COVID-19 .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Name
Email *

	Sorry, but the email address you supplied was invalid.

Acid Stable Protease

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Natural
Products